4-AcO-MiPT

Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since July 18, 2019.²⁶ Production, import with intent to market, administration to others, and trading are criminal offenses.²⁷ Possession is prohibited but not subject to criminal penalties.²⁸ Ordering may be considered incitement to place on the market.

4-AcO-MiPT is a designated substance (指定薬物) in Japan, a category that article 2(15) of the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices defines separately from the stimulants, narcotics, psychotropics, opium and poppy straw governed by their own statutes. Item 8 of article 1 of Ministerial Ordinance No. 14 of 2007 designates 4-acetoxy-N-isopropyl-N-methyltryptamine and its salts, and article 2 of the same ordinance fixes the medical and other uses that stay lawful for this substance: academic research or testing by state bodies, local authorities, universities and other listed public institutions, official testing and inspection under the Act, criminal forensics, and any further use that the Minister of Health, Labour and Welfare has recognised as not liable to cause harm to the human body. Ministerial Ordinance No. 41 of 2015, which amended that ordinance, added the substance; the Ministry of Health, Labour and Welfare promulgated it on 25 March 2015 and it came into force on 4 April 2015, ten days after promulgation, the date the Ministry's English list of designated substances gives as the date of enforcement. Article 76-4 of the Act forbids manufacturing, importing, selling, transferring, possessing, purchasing or receiving a designated substance for any purpose outside those medical and other uses, and forbids using it for such a purpose. Article 84 item 28 punishes that conduct with up to 3 years imprisonment or a fine of up to 3 million yen, or both; article 83-9 raises the maximum to 5 years imprisonment or a fine of up to 5 million yen, or both, where the manufacture, import, sale or transfer is carried on as a business, or where the substance is stored or displayed for sale or transfer as a business.

Norway's Narkotikalisten expressly lists 4-AcO-MiPT and identifies it as 4-acetoksy-N-metyl-N-isopropyltryptamin. The substance is listed directly in the national narcotics regulation, rather than through analogue coverage.

4-AcO-MIPT är uttryckligen upptaget som hälsofarlig vara i bilagan till förordning (1999:58). Lagen (1999:42) förbjuder utan tillstånd bland annat införsel, överlåtelse, framställning, försäljningsutbud och innehav; uppsåtliga överträdelser av de angivna förbuden är straffbelagda.

4-AcO-MiPT is a Class A controlled drug in the United Kingdom, caught by Schedule 2 to the Misuse of Drugs Act 1971 in two steps rather than named in it.³⁵ Paragraph 1(b) of Part I of that Schedule covers any compound structurally derived from tryptamine or from a ring-hydroxy tryptamine by substitution at the nitrogen atom of the side chain to any extent with alkyl or alkenyl substituents. That paragraph brings the parent phenol 4-HO-MiPT within paragraph 1, because 4-HO-MiPT is the 4-hydroxy tryptamine modified only at the side-chain nitrogen, by a methyl and an isopropyl substituent. Paragraph 3 then reaches any ester or ether of a substance specified in paragraph 1 or 2 that is not itself specified in Part II of the Schedule, and 4-AcO-MiPT is the acetate ester of 4-HO-MiPT. Coverage runs through paragraph 3 rather than through paragraph 1(b) itself, because the ring modifications paragraph 1(b) enumerates extend only to alkyl, alkoxy, haloalkyl, thioalkyl, alkylenedioxy and halide substituents, and an acyloxy group is none of these. Part II lists no acetoxy tryptamine, and the ester provision in its paragraph 2A runs only to cannabinol, to cannabinol derivatives and to substances specified in paragraphs 1(ac), 1(c), 1(ca) and 1(d) of that Part, so the exception in paragraph 3 leaves the acetate in Part I. Section 2(1)(b) of the Act makes the substances specified in Part I Class A drugs. Section 25 and Schedule 4 then set the maximum penalties by class, and no offence in Schedule 4 carries a higher maximum for a Class B or Class C drug than for a Class A drug. On indictment, production, supply or offering to supply, and possession with intent to supply each carry life imprisonment or a fine or both where a Class A drug is involved, against fourteen years for a Class B or Class C drug, and simple possession carries seven years or a fine or both, against five years for a Class B drug and two years for a Class C drug.

4-AcO-MiPT is expressly scheduled in Finland as a consumer-market-banned psychoactive substance, not merely inferred from an analogue or generic class rule. Decree 1101/2025's replacement list continues to name it, and the later Decree 650/2026 removed only 4-BMC, 2-MMC and NEP. The separate current narcotics schedule does not list 4-AcO-MiPT; accordingly, the specific consumer-market ban applies. Under Narcotics Act section 5(2), the specific consumer-market ban covers manufacture, import, storage, offering for sale and transfer, with statutory research and industrial-use pathways; it does not by its wording impose the narcotics category's general possession/use ban. Other Finnish laws may apply according to the facts of a particular transaction.

The exact name 4-AcO-MiPT is not printed in the Annex 6 named-entry sequence, but the binding ordinance expressly extends control to esters of substances listed in Annexes 1–6. 4-HO-MIPT is item 83 in Annex 6, and 4-AcO-MiPT is its acetate ester. Verzeichnis e is the Swiss presumed-narcotic-like-effects category, not Verzeichnis d; the schedule provisions establish controlled status and ester coverage but do not impose a universal possession or penalty rule for every factual scenario.

Not specifically scheduled under the Controlled Substances Act.³⁴ However, it may be considered an analogue of psilocin (4-HO-DMT), a Schedule I substance. Sale for human consumption or possession with intent to ingest could potentially be prosecuted under the Federal Analogue Act.